|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Altekruse SF, Henley SJ, Cucinelli JE and
McGlynn KA: Changing hepatocellular carcinoma incidence and liver
cancer mortality rates in the United States. Am J Gastroenterol.
109:542–553. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang G, Li R, Deng Y and Zhao L:
Conditional survival of patients with hepatocellular carcinoma:
Results from the Surveillance, Epidemiology, and End Results
registry. Expert Rev Gastroenterol Hepatol. 12:515–523. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu L, Kim Y, Spolverato G, Gani F and
Pawlik TM: Racial disparities in treatment and survival of patients
with hepatocellular carcinoma in the United States. Hepatobiliary
Surg Nutr. 5:43–52. 2016.PubMed/NCBI
|
|
6
|
Villanueva A: Hepatocellular Carcinoma. N
Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Link A and Kupcinskas J: MicroRNAs as
non-invasive diagnostic biomarkers for gastric cancer: Current
insights and future perspectives. World J Gastroenterol.
24:3313–3329. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Harada K, Baba Y, Ishimoto T, Shigaki H,
Kosumi K, Yoshida N, Watanabe M and Baba H: The role of microRNA in
esophageal squamous cell carcinoma. J Gastroenterol. 51:520–530.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen B, Xia Z, Deng YN, Yang Y, Zhang P,
Zhu H, Xu N and Liang S: Emerging microRNA biomarkers for
colorectal cancer diagnosis and prognosis. Open Biol. 9:1802122019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rawat M, Kadian K, Gupta Y, Kumar A, Chain
PSG, Kovbasnjuk O, Kumar S and Parasher G: MicroRNA in pancreatic
cancer: From biology to therapeutic potential. Genes (Basel).
10:7522019. View Article : Google Scholar
|
|
12
|
Oura K, Morishita A and Masaki T:
Molecular and functional roles of MicroRNAs in the progression of
hepatocellular carcinoma-A review. Int J Mol Sci. 21:83622020.
View Article : Google Scholar
|
|
13
|
Zhang L, Yang L, Liu X, Chen W, Chang L,
Chen L, Loera S, Chu P, Huang WC, Liu YR and Yen Y: MicroRNA-657
promotes tumorigenesis in hepatocellular carcinoma by targeting
transducin-like enhancer protein 1 through nuclear factor kappa B
pathways. Hepatology. 57:1919–1930. 2013. View Article : Google Scholar
|
|
14
|
Song Z, Yu Z, Chen L, Zhou Z, Zou Q and
Liu Y: MicroRNA-1181 supports the growth of hepatocellular
carcinoma by repressing AXIN1. Biomed Pharmacother. 119:1093972019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong QW, Lung RW, Law PT, Lai PB, Chan KY,
To KF and Wong N: MicroRNA-223 is commonly repressed in
hepatocellular carcinoma and potentiates expression of Stathmin1.
Gastroenterology. 135:257–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang R, Zhao N, Li S, Fang JH, Chen MX,
Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses
angiogenesis and metastasis of hepatocellular carcinoma by
inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology.
58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang W, Ju HY and Tian XF: Hsa-miR-4730 as
a new and potential diagnostic and prognostic indicators for
pancreatic cancer. Eur Rev Med Pharmacol Sci. 24:8801–8811.
2020.PubMed/NCBI
|
|
18
|
Union for International Cancer Control:
TNM Classification of Malignant Tumours. Brierley JD, Gospodarowicz
MK and Wittekind C: 8th edition. John Wiley & Sons, Inc;
Hoboken, NJ: 2017
|
|
19
|
The Japan Society of Hepatology: Clinical
Practice Guidelines for Hepatocellular Carcinoma 2017. Kanehara
& Co Ltd; Tokyo: 2017
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
21
|
Liu L, Zhang S, Hu L, Liu L, Guo W and
Zhang J: HMGA1 participates in MHCC97H cell proliferation and
invasion through the ILK/Akt/GSK3β signaling pathway. Mol Med Rep.
16:9287–9294. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fusco A and Fedele M: Roles of HMGA
proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chiappetta G, Avantaggiato V, Visconti R,
Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti
V, Santoro M, et al: High level expression of the HMGI (Y) gene
during embryonic development. Oncogene. 13:2439–2446.
1996.PubMed/NCBI
|
|
24
|
Wang Y, Hu L, Zheng Y and Guo L: HMGA1 in
cancer: Cancer classification by location. J Cell Mol Med.
23:2293–2302. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sumter TF, Xian L, Huso T, Koo M, Chang
YT, Almasri TN, Chia L, Inglis C, Reid D and Resar LM: The high
mobility group A1 (HMGA1) transcriptome in cancer and development.
Curr Mol Med. 16:353–393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi M, Lv X, Zhu M, Dong Y, Hu L, Qian Y,
Fan C and Tian N: HMGA1 promotes hepatocellular carcinoma
proliferation, migration, and regulates cell cycle via miR-195-5p.
Anticancer Drugs. 33:e273–e285. 2022. View Article : Google Scholar
|
|
27
|
Wan T, Zheng J, Yao R, Yang S, Zheng W and
Zhou P: LncRNA DDX11-AS1 accelerates hepatocellular carcinoma
progression via the miR-195-5p/MACC1 pathway. Ann Hepatol.
20:1002582021. View Article : Google Scholar
|
|
28
|
Liu LX, Liu B, Yu J, Zhang DY, Shi JH and
Liang P: SP1-induced upregulation of lncRNA CTBP1-AS2 accelerates
the hepatocellular carcinoma tumorigenesis through targeting CEP55
via sponging miR-195-5p. Biochem Biophys Res Commun. 533:779–785.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang D, Wei Y, Zhu J and Wang F: Long
non-coding RNA SNHG1 functions as a competitive endogenous RNA to
regulate PDCD4 expression by sponging miR-195-5p in hepatocellular
carcinoma. Gene. 714:1439942019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reeves R: Molecular biology of HMGA
proteins: Hubs of nuclear function. Gene. 277:63–81. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chan J, Ko FC, Yeung YS, Ng IO and Yam JW:
Integrin-linked kinase overexpression and its oncogenic role in
promoting tumorigenicity of hepatocellular carcinoma. PLoS One.
6:e169842011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Revathidevi S and Munirajan AK: Akt in
cancer: Mediator and more. Semin Cancer Biol. 59:80–91. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Spokoini R, Kfir-Erenfeld S, Yefenof E and
Sionov RV: Glycogen synthase kinase-3 plays a central role in
mediating glucocorticoid-induced apoptosis. Mol Endocrinol.
24:1136–1150. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Koundouros N and Poulogiannis G:
Phosphoinositide 3-Kinase/Akt signaling and redox metabolism in
cancer. Front Oncol. 8:1602018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nakanishi F, Ohkawa K, Ishida H, Hosui A,
Sato A, Hiramatsu N, Ueda K, Takehara T, Kasahara A, Sasaki Y, et
al: Alteration in gene expression profile by full-length hepatitis
B virus genome. Intervirology. 48:77–83. 2005. View Article : Google Scholar : PubMed/NCBI
|
